Retained by Stueve Siegel Hanson LLP
Dr. Bradford was retained by plaintiffs, through their counsel, to submit a report in support of their motion for class certification in Searcy, et al. v. Gilead Sciences, Inc. (E.D. Mo. No. 4:20-cv-1523-MTS).
Named plaintiffs Jonathan Searcy and Ervin Kirk alleged Gilead Sciences engaged in unlawful conduct related to the sale and marketing of the HIV treatment drug tenofovir disoproxil fumarate (TDF). They claim Gilead misrepresented the safety of an alternative drug, tenofovir alafenamide (TAF), delayed its FDA approval to boost TDF sales, and charged Missouri patients artificially high prices for TDF during the class period (2003–2015), resulting in unjust enrichment.
Using widely accepted economic and pharmaceutical industry evidence (including data from Gilead), Dr. Bradford developed an economically sound methodology to calculate damages for the Missouri purchaser class resulting from Gilead's unlawful conduct. He provided two distinct methodologies to identify the benefit of the bargain damages under the MMPA and unjust enrichment damages.
Prof. Bradford is an economics and public policy professor with over 20 years of experience in health economics. His expertise covers the healthcare industry, hospitals, health insurance, and pharmaceuticals.
